The Nonmelanomatous Skin Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Nonmelanomatous Skin Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Nonmelanomatous Skin Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Nonmelanomatous Skin Cancer and features dormant and discontinued products.
GlobalData tracks 83 drugs in development for Nonmelanomatous Skin Cancer by 73 companies/universities/institutes. The top development phase for Nonmelanomatous Skin Cancer is phase ii with 43 drugs in that stage. The Nonmelanomatous Skin Cancer pipeline has 77 drugs in development by companies and six by universities/ institutes. Some of the companies in the Nonmelanomatous Skin Cancer pipeline products market are: Bristol-Myers Squibb, Incyte and F. Hoffmann-La Roche.
The key targets in the Nonmelanomatous Skin Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), and Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3).
The key mechanisms of action in the Nonmelanomatous Skin Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with nine drugs in Pre-Registration. The Nonmelanomatous Skin Cancer pipeline products include 18 routes of administration with the top ROA being Intravenous and 16 key molecule types in the Nonmelanomatous Skin Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.
Nonmelanomatous Skin Cancer overview
Nonmelanoma skin cancer comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), originating from skin cells other than melanocytes. Linked to sun exposure, these cancers often appear on sun-exposed areas. BCC, the most prevalent, usually presents as a pearly bump or a sore that doesn’t heal. SCC may appear as a scaly patch or a firm, red nodule. While rarely lethal, if left untreated, they can invade nearby tissues. Treatments include surgical removal, topical medications, radiation, or in advanced cases, targeted therapies. Early detection through regular skin checks aids in prompt treatment, increasing the chances of successful outcomes.
For a complete picture of Nonmelanomatous Skin Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
